Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

ctDNA, a Biomarker of Residual Disease and Tumor Response in Gastrointestinal Cancers

Monitoring ctDNA is a promising new approach to personalized cancer medicine that may provide real-time information about the evolution of tumors. We evaluated how changes in ctDNA predicted response to treatment across metastatic gastrointestinal cancer patients on treatment and compared ctDNA to standard tumor markers. Longitudinal ctDNA assessment both in the curative and metastatic settings may provide insight into the dynamic changes due to treatment.

Video Overview:

Aparna Raj Parikh, MD

Massachusetts General Hospital

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.